ProMIS Neurosciences Reveals Strengthening Of Global Intellectual Property Portfolio

The European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences' product candidate, PMN310, for the treatment of Alzheimer's disease (AD) (EP 18 835 520.0; JP7448174; AU2022201737). PMN310 is the Company's novel monoclonal antibody that is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ), which are believed to be a major driver of AD.